Agent Granted Priority Review to Treat Non-Hodgkin Lymphoma – Curetoday.com
Curetoday.com |
Agent Granted Priority Review to Treat Non-Hodgkin Lymphoma
Curetoday.com Axicabtagene ciloleucel (KTE-C19; axi-cel) was granted a priority review by the Food and Drug Administration (FDA) for the treatment of transplant-ineligible … Kite catches the inside track on the last leg of a race to the finish line … |
